KorrekturOpen Access
Correction to “Setmelanotide in Bardet‐Biedl Syndrome: A 52‐Week Comparison of Phase 3 Trial Participants With a Matched Registry Cohort”
Obesity · 2026-06 · 34 (6) · 1354-1354
DOI: 10.1002/oby.70194 ↗Kurz gefasst
Korrektur in der Zeitschrift Obesity, online erschienen am 22.03.2026. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
(2026). Correction to “Setmelanotide in Bardet‐Biedl Syndrome: A 52‐Week Comparison of Phase 3 Trial Participants With a Matched Registry Cohort”. Obesity, 34(6), 1354-1354. https://doi.org/10.1002/oby.70194
Vancouver
Correction to “Setmelanotide in Bardet‐Biedl Syndrome: A 52‐Week Comparison of Phase 3 Trial Participants With a Matched Registry Cohort”. Obesity. 2026;34(6):1354-1354. doi:10.1002/oby.70194
BibTeX
@article{euvimed2026,
title = {Correction to “Setmelanotide in Bardet‐Biedl Syndrome: A 52‐Week Comparison of Phase 3 Trial Participants With a Matched Registry Cohort”},
journal = {Obesity},
year = {2026},
volume = {34},
number = {6},
pages = {1354--1354},
doi = {10.1002/oby.70194}
}
EUVIMED